Ovid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights Platform

NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced multiple presentations across its rare neurological disease platform are available on the 2020 American Academy of Neurology (AAN) Science Highlights platform. The presentations were originally slated for discussion at the AAN 72nd Annual Meeting scheduled for April 25-May 1, which was cancelled due to the COVID-19 pandemic. The abstracts were also published in the online supplement to Neurology.

The presentations available on the AAN Science Highlights online platform include the following:

Presentations on OV101 (gaboxadol) in Neurodevelopmental Disorders:

Title:

Topic: Child Neurology and Developmental Neurology 

Title:

Topic: Child Neurology and Developmental Neurology 

Title:

Topic: Child Neurology and Developmental Neurology 

Title:

Topic: Child Neurology and Developmental Neurology 

Title:

Topic: Child Neurology and Developmental Neurology 

Title:

Topic: Child Neurology and Developmental Neurology 

Title:

Topic: Child Neurology and Developmental Neurology 

Title:

Topic: Child Neurology and Developmental Neurology 

Presentations on OV935/TAK935 (soticlestat) in Rare Developmental and Epileptic Encephalopathies (DEE):

Title:

Topic: Epilepsy/Clinical Neurophysiology (EEG) 

Title:

Topic: Epilepsy/Clinical Neurophysiology (EEG) 

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The Company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935/TAK935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).

For more information on Ovid, please visit .

Contacts

Investors and Media:

Ovid Therapeutics Inc.

Investor Relations & Public Relations

Or

Investors:

Steve Klass

Burns McClellan, Inc.



(212) 213-0006

Media:

Katie Engleman

1AB



(919) 333-7722